Down syndrome (ds) is the most common mental retardation syndrome in the world. It is more prevalent in males. The causes of the syndrome are multiple. The most common treatment is mental retardation therapy. Down syndrome (ds) is cured by early intervention.
The actual rate of DS is much lower than the national rate, as reported by the US National Down Syndrome Congress: The true annual number of DS babies born in the US is estimated at about 200,000, less than 5% of all infants with Down syndrome in the UK and 8.5% of all DS children being born in the U.S..\n
Current treatment is effective in many respects but a significant proportion of patients experience significant relapse within two years. The outcome of treatment appears to be influenced by the type of medication used. The most effective treatment is a combination of medication to control symptoms and behaviour therapy. However, the effectiveness of medication alone is very limited and treatment in which behaviour, medication and psychotherapy all work together to achieve remission is the most favourable in terms of relapse rates.
Down syndrome (ds) is a genetically complex disorder characterised by chromosomal rearrangements, which are often duplicated in mosaicing. The majority of cases are trisomy 21 and DYT6 is responsible for half of the DS population. Children and adults with phenotypically DS are at increased risk of developing mental disorders, which represent a major health care burden worldwide. The current understanding of the mechanisms that lead to the phenotype in DS as well as the treatment of psychiatric disorders for this population is in its infancy.
Signs of ds include increased hair growth (gooseflesh), overgrowth of the ear-folds, large head, broad forehead (macrostomia), broad nose, broad chin, a flat nasal bridge, large, wrinkly eyes, deep-set eyes, short neck, narrow head width, small ear-folds, short upper arm and long legs and feet. The facial features of ds may have no relation to IQ and may signify a special type of intellectual disability. The physical manifestations of ds are not very specific; they are sometimes overlooked. Some of the features of ds may be due to its effects on the normal growth pattern of the brain.
It seems probable that genes, environmental factors, and a complex mix of factors, all influence the health of individuals with DS and their progeny. Because of the genetic variability of DS, many genetic syndromes and conditions have already been identified, yet few are universally prevalent in every individual with DS. DS may even be a sporadic (nonfamilial) condition of variable penetrance. To make appropriate decisions about prenatal treatment, genetic counseling, and the care of affected infants and children, we need to continue to evaluate and refine our understanding of the complex genetic factors that are probably responsible for the complex health issues of individuals with DS.
In a controlled study of preschoolers with Down syndrome with and without a specific intervention, in-room use of a harness system was not effective as a treatment for balance and physical function.
Only a few of new drugs for ds could be identified. Overall, there is a lack of effective new treatments for ds. There is a challenge in ds research in order to find a new drug for ds that has the best chance to succeed. There are many potential new drugs for repairing, repairing, or targeting enzymes. However, there are several possible side effects. It would benefit ds research in order to select the most effective drugs and to minimize side effects, using the best of current research.
We conclude that these devices and programs can beneficially alter motor skills in children with DS. It can provide an increase in body weight, endurance, and postural stability and mobility tasks. There might be a benefit in maintaining social interaction levels and communication skills as well.
Data from a recent study provides preliminary evidence that partial BWSTT harness is safe for use in non-impaired older adults. Data from a recent study warrant further research designed to inform the provision of this treatment to older adults.
Allowing patients with Down's syndrome to participate in a clinical trial provides a valuable method to obtain further and accurate information on some aspects of their condition. It also offers patients and parents with more options than the current information presented in the medical records. Such information may prove helpful in deciding to join a clinical trial, when choosing an individual physician, or when discussing future health plans. The ultimate goal is to create a clinical trial that is representative of the general population, and that incorporates most or all the issues affecting each individual patient.
The type of enrichment used is an important factor in the ability to overcome the negative effects of the partial weight support harness. Thus, the type of play equipment and the design of the harness system are a major determinant in the ability to overcome the negative effects on motor skills with a partial weight support harness in children with Down's syndrome. The data should serve as preliminary information for a design that includes a variety of enrichment equipment for the different children's motor abilities.